Osteoprotegerin predicts progression of chronic heart failure: Results from CORONA

Circulation: Heart Failure

Volumn 4, Issue 2, 2011, Pages 145-152

  Ueland, Thor ^a,b   Dahl, Christen P ^a   Kjekshus, John ^b   Hulthe, Johannes ^c   Böhm, Michael ^e   Mach, François ^f   Goudev, Assen ^g   Lindberg, Magnus ^d   Wikstrand, John ^c   Aukrust, Pål ^a,b   Gullestad, Lars ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

^e SAARLAND UNIVERSITY   (Germany)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

Author keywords

Heart failure; Osteoprotegerin; Risk prediction

Indexed keywords

OSTEOPROTEGERIN; PLACEBO; ROSUVASTATIN; BIOLOGICAL MARKER; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PYRIMIDINE DERIVATIVE; SULFONAMIDE; TNFRSF11B PROTEIN, HUMAN;

AGED; ARTICLE; CHRONIC DISEASE; DEATH; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STROKE; SURVIVAL RATE; TREATMENT OUTCOME; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EUROPE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; TIME;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHRONIC DISEASE; EUROPE; FEMALE; FLUOROBENZENES; HEART FAILURE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIER ESTIMATE; LIPIDS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PYRIMIDINES; RISK ASSESSMENT; RISK FACTORS; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 79955929820     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.110.957332     Document Type: Article

References (19)

1. Ueland T, Aukrust P, Damas JK, Gullestad L, Yndestad A. The tumor necrosis factor superfamily in heart failure. Future Cardiol. 2009;2:101-111.
2. Mann DL. Recent insights into the role of tumor necrosis factor in the failing heart. Heart Fail Rev. 2001;6:71-80. (Pubitemid 32328170)
3. Wong SC, Fukuchi M, Melnyk P, Rodger I, Giaid A. Induction of cyclooxygenase- 2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure. Circulation. 1998;98:100-103. (Pubitemid 28317888)
4. Ueland T, Yndestad A, Oie E, Florholmen G, Halvorsen B, Froland SS, Simonsen S, Christensen G, Gullestad L, Aukrust P. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation. 2005;111:2461-2468. (Pubitemid 40696134)
5. Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, Schett G. The osteoprotegerin/RANK/RANKL system: A bone key to vascular disease. Expert Rev Cardiovasc Ther. 2006;4:801-811. (Pubitemid 46017520)
6. Papadopouli AE, Klonaris CN, Theocharis SE. Role of OPG/RANKL/RANK axis on the vasculature. Histol Histopathol. 2008;23: 497-506. (Pubitemid 351552335)
7. Nybo M, Rasmussen LM. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: A systematic literature review. Eur J Endocrinol. 2008;159:603-608.
8. Ueland T, Jemtland R, Godang K, Kjekshus J, Hognestad A, Omland T, Squire IB, Gullestad L, Bollerslev J, Dickstein K, Aukrust P. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol. 2004;44:1970-1976. (Pubitemid 39473280)
9. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Janosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-2261. (Pubitemid 350190755)
10. Wedel H, McMurray JJ, Lindberg M, Wikstrand J, Cleland JG, Cornel JH, Dunselman P, Hjalmarson A, Kjekshus J, Komajda M, Kuusi T, Vanhaecke J, Waagstein F. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): Incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. 2009;11:281-291.
11. Cleland JG, McMurray JJ, Kjekshus J, Cornel JH, Dunselman P, Fonseca C, Hjalmarson A, Korewicki J, Lindberg M, Ranjith N, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J. Plasma concentration of aminoterminal pro-brain natriuretic peptide in chronic heart failure: Prediction of cardiovascular events and interaction with the effects of rosuvastatin: A report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol. 2009;54:1850-1859.
12. McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamensky G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the controlled rosuvastatin multinational trial in heart failure (CORONA): A Retrospective Analysis. Circulation. 2009;120:2188-2196.
13. Ueland T, Bollerslev J, Godang K, Muller F, Froland SS, Aukrust P. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess-possible role in bone homeostasis. Eur J Endocrinol. 2001;145:685-690. (Pubitemid 33133673)
14. Harrell FE, Jr., Lee KL, Mark DB. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387. (Pubitemid 26072233)
15. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: Model specific population value and confidence interval estimation. Stat Med. 2004;23:2109-2123. (Pubitemid 38968032)
16. Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Smith C, Herlitz J, Aukrust P, Hartford M, Caidahl K. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol. 2008;51:627-633. (Pubitemid 351193104)
17. Omland T, Drazner MH, Ueland T, Abedin M, Murphy SA, Aukrust P, de Lemos JA. Plasma osteoprotegerin levels in the general population: Relation to indices of left ventricular structure and function. Hypertension. 2007;49:1392-1398. (Pubitemid 46809385)
18. Nellemann B, Gormsen LC, Dollerup J, Schmitz O, Mogensen CE, Rasmussen LM, Nielsen S. Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diabetes Care. 2007; 30:3122-3124. (Pubitemid 350255261)
19. Mathur N, Ramasubbu K, Mann DL. Spectrum of pleiotropic effects of statins in heart failure. Heart Fail Clin. 2008;4:153-161 (Pubitemid 351539133)